No Data
No Data
Jefferies Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,245
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,242
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
Regeneron Pharma Price Target Maintained With a $1300.00/Share by BMO Capital
Regeneron Pharmaceuticals Worst Performer in the S&P 500 and Nasdaq 100 So Far Today -- Data Talk
No Data
No Data